Doosan Tesna (KOSPI 131970) 2026 outlook: wafer-level testing in the AI semiconductor value chain, Doosan Group ownership benefits and risks, fabless customer diversification opportunity, and what foreign investors need to know about this Korean back-end semiconductor services specialist.
Hanon Systems (KOSPI 018880) 2026 stock outlook: analyzing EV thermal management opportunity, battery thermal management systems, heat pump technology, competitive positioning against Denso and Valeo, and what foreign investors need to know about this Korean auto components supplier.
SK Biopharmaceuticals (KOSPI 326030) 2026 outlook: XCOPRI (cenobamate) US prescription growth, direct-sales model economics, CNS pipeline depth, competitive position in epilepsy treatment, and what foreign investors need to know before buying a Korean biotech.
SK Square (KOSPI 402340) 2026 outlook: analyzing the NAV discount structure, SK Hynix equity stake value, portfolio assets including 11Street, Tmap Mobility, and OneStore, and what foreign investors need to know about investing in a Korean ICT holding company.
Kakao Pay (KOSPI 377300) 2026 stock outlook: analyzing the path to profitability, Ant Financial shareholding risks, multi-license fintech expansion, and what foreign investors need to know about withholding tax and ADR availability.